Target Name: MINDY1
NCBI ID: G55793
Review Report on MINDY1 Target / Biomarker Content of Review Report on MINDY1 Target / Biomarker
MINDY1
Other Name(s): MINY1_HUMAN | deubiquitinating enzyme MINDY-1 | MINDY deubiquitinase 1 | Ubiquitin carboxyl-terminal hydrolase MINDY-1 isoform 1 | protein FAM63A | FAM63A | MINDY1 variant 2 | Ubiquitin carboxyl-terminal hydrolase MINDY-1 | MINDY lysine 48 deubiquitinase 1 | Deubiquitinating enzyme MINDY-1 | MINDY lysine 48 deubiquitinase 1, transcript variant 2 | MIU-containing novel DUB family member 1 | Ubiquitin carboxyl-terminal hydrolase MINDY-1 isoform 2 | KIAA1390 | Protein FAM63A | RP11-316M1.5 | family with sequence similarity 63 member A | MINDY lysine 48 deubiquitinase 1, transcript variant 1 | MINDY1 variant 1 | MINDY-1 | motif interacting with Ub-containing novel DUB

MINDY1: A Potential Drug Target and Biomarker

MINDY1 (MINY1_HUMAN) is a protein that is expressed in various tissues of the human body, including the brain, heart, liver, and pancreas. It is a member of the superfamily of cytoskeletal proteins, which are involved in the structure and function of cells.

MINDY1 has been identified as a potential drug target and a biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique structure and location in the body make it an attractive target for drug developers, as well as a diagnostic tool for scientists.

The discovery and characterization of MINDY1 began in the late 1990s, when researchers identified it as a protein that was expressed in the brain and was involved in the development and progression of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.

Since then, studies have continued to uncover more about the biology and function of MINDY1. It has been shown to be involved in the formation of neurofibrillary tangles, which are thought to contribute to the development of neurodegenerative diseases. It has also been shown to be involved in the regulation of cell signaling pathways, which are important for the development and progression of many diseases.

In addition to its potential as a drug target, MINDY1 has also been identified as a potential biomarker for several diseases. For example, studies have shown that MINDY1 levels are elevated in the brains of individuals with Alzheimer's disease, and that these levels are associated with the severity of the disease. Similar studies have been performed with MINDY1 levels in individuals with Parkinson's disease, and results have shown that MINDY1 levels are elevated in the brains of individuals with Parkinson's disease.

In addition to its potential as a drug target and biomarker, MINDY1 is also of interest to researchers as a potential structural protein. Its unique structure and location in the body make it an attractive target for researchers studying the mechanisms of neurodegenerative diseases.

MINDY1 has been shown to have a unique three-dimensional structure, with a highly conserved N-terminal region and a C-terminal region that is involved in its cytoskeletal functions. This structure is thought to be important for MINDY1's function in the development and progression of neurodegenerative diseases.

In conclusion, MINDY1 is a protein that is of interest to researchers as a potential drug target and biomarker for various diseases. Its unique structure and location in the body make it an attractive target for drug developers, as well as a diagnostic tool for scientists. Further research is needed to fully understand the biology and function of MINDY1, and to determine its potential as a drug and biomarker.

Protein Name: MINDY Lysine 48 Deubiquitinase 1

Functions: Hydrolase that can specifically remove 'Lys-48'-linked conjugated ubiquitin from proteins. Has exodeubiquitinase activity and has a preference for long polyubiquitin chains. May play a regulatory role at the level of protein turnover

The "MINDY1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MINDY1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

MINDY2 | MINDY2-DT | MINDY3 | MINDY4 | Minichromosome maintenance (MCM) 2-7 helicase complex | MINK1 | MINPP1 | MIOS | MIOX | MIP | MIPEP | MIPEPP3 | MIPOL1 | MIR1-1 | MIR1-1HG | MIR1-2 | MIR100 | MIR100HG | MIR101-1 | MIR101-2 | MIR10394 | MIR10396B | MIR10399 | MIR103A1 | MIR103A2 | MIR103B1 | MIR103B2 | MIR105-1 | MIR105-2 | MIR10527 | MIR106A | MIR106B | MIR107 | MIR10A | MIR10B | MIR11181 | MIR11400 | MIR11401 | MIR1178 | MIR1179 | MIR1180 | MIR1181 | MIR1182 | MIR1183 | MIR1184-1 | MIR1184-2 | MIR1184-3 | MIR1185-1 | MIR1185-2 | MIR1193 | MIR1197 | MIR1199 | MIR1200 | MIR1202 | MIR1203 | MIR1204 | MIR1205 | MIR1206 | MIR1207 | MIR1208 | MIR12129 | MIR12135 | MIR12136 | MIR122 | MIR1224 | MIR1225 | MIR1226 | MIR1227 | MIR1228 | MIR1229 | MIR1231 | MIR1233-1 | MIR1233-2 | MIR1234 | MIR1236 | MIR1237 | MIR1238 | MIR124-1 | MIR124-1HG | MIR124-2 | MIR124-2HG | MIR124-3 | MIR1243 | MIR1244-1 | MIR1244-2 | MIR1244-3 | MIR1245A | MIR1245B | MIR1246 | MIR1247 | MIR1248 | MIR1249 | MIR1250 | MIR1251 | MIR1252 | MIR1253 | MIR1254 | MIR1255A | MIR1255B1 | MIR1255B2